Infections Due to Group A Streptococcus: New Concepts and Potential Treatment Strategies

Annals of the Academy of Medicine Singapore

Volumn 26, Issue 5, 1997, Pages 691-693

  Norrby, S R ^a   Norrby Teglund, A ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytokines; Necrotizing fasciitis; Streptococcal toxic shock syndrome; Superantigens

Indexed keywords

ANTIINFECTIVE AGENT; CLINDAMYCIN; IMMUNOGLOBULIN;

ANIMAL; HUMAN; IMMUNOLOGY; NECROTIZING FASCIITIS; REVIEW; SEPTIC SHOCK; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES; SWEDEN;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINDAMYCIN; FASCIITIS, NECROTIZING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SWEDEN;

EID: 0031216299     PISSN: 03044602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Cone L A, Woodard D R, Schlievert P M, Tomory G S. Clinical and bacteriological observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987; 317:146-9.
2. Martin P R, Høijby E A Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis 1990; 22:421-9.
3. Stromberg A, Romanus V, Burman L G. Outbreak of group A Streptococcal bacteremia in Sweden: an epidemiological and clinical study J Infect Dis 1991; 164:595-8.
4. Gaworzewska E, Colman G. Changes in the pattern of infection caused by Streptococcus pyogenes. Epidemiol Infect 1988; 100:257-69.
5. Davies H D, McGeer A, Schwartz B, Cann D, Simor A E, Low D E. Invasive group A Streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 1996; 335.547-54
6. Kotb M. Role of superantigens in the pathogenesis of infectious diseases and their sequelae. Curr Opin Infect Dis 1992; 5:364-74.
7. Kotb M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995; 8:411-26.
8. Musser J M, Hauser A R, Kim M H, Schlievert P M, Nelson K, Selander R K. Streptococcus pyogenes causing toxic shock-luce syndrome and other invasive diseases: clonal diversity and pyrogenk exotoxin expression Proc Natl Acad Sci USA 1991; 88:2668-72.
9. Watanve-Onishi R, Low D E, McGeer A, et al. Selective depletion of Vβ-bearing T cells in patients with severe invasive group A Streptococcal infections and Streptococcal toxic shock syndrome. J Infect Dis 1995; 171:74-84.
10. Stevens D L, Tanner M H, Winship J, Swartz R, Ries K M, Schlievert P M, et al Severe group A Streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin. N Engl J Med 1989; 321:1-7.
11. Norrby-Teglund A, Pauksen K, Holm S E, Norgren M. Relation between low capacity of human sera to inhibit Streptococcal mitogens and serious manifestations of disease. J Infect Dis 1994; 170:588-91.
12. Stevens D L, Gibbons A E, Bergstrom R, Winn T. The Eagle effect revisited: efficacy of clindamycin, erythromycin and penicillin in the treatment of Streptococcal myositis. J Infect Dis 1988; 158:23-8.
13. Betriu C M, Sanches A, Gomez M, Cruceyra A, Picazo J J. Antibiotic susceptibility of group A streptococci: a 6-year follow-up. Antimicrob Agents Chemother 1993; 37:1717-9.
14. Kaul R, McGeer A. Intravenous immunoglobulin (IVIG) therapy in streptococcal toxic shock syndrome: results of a matched case-control study. Canadian Infectious Diseases Society, Ontario Streptococcal Study Project [abstract LM 68]. Proceedings of the 35th ICAAC, 1995. Washington, DC: American Society of Microbiology, 1995.
15. Norrby-Teglund A, Kaul R, Low D E, McGeer A, Newton D W, Andersson J, et al. Plasma from patients with severe invasive group A Streptococcal infections treated with normal polyspecific IgG inhibits Streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996; 156.3057-64
16. Sellers B J, Woods M L, Morris S E, Saflle J R Necrotizing group A Streptococcal infections associated with Streptococcal toxic shock syndrome. Am J Surg 1996, 172:523-8.